Datamonitor Healthcare’s PharmaVitae team explores the value in the flurry of recent deals, shedding light on incentives and how they may influence the market and future deal-making. With short-term challenges seeing top line revenue from the PharmaVitae portfolio to grow by a modestly in 2016, transactions will aim to counter industry headwinds.
Publisher: Datamonitor Healthcare
Published: 7th September 2016
Number of pages:44
Datamonitor Healthcare’s PharmaVitae team explores the value in the flurry of recent deals, shedding light on incentives and how they may influence the market and future deal-making. With short-term challenges seeing top line revenue from the PharmaVitae portfolio to grow by a modestly in 2016, transactions will aim to counter industry headwinds. Amidst market turbulence, companies will continue their search for mid-sized pipeline-centric growth assets, given increasing cash balances and uncertain revenue projections. Will M&A continue to remain an appetizing strategic policy to fuel further consolidation?
Explore and visualize M&A dynamics in the pharmaceutical and biotechnology industries:
major deal discussion
Key questions answered
Explore and assess recent deals based on deal size and company type
How is the industry using M&A as a vehicle to propel a strategy for growth?
Delve deeper into the largest deals of 2015
What’s the outlook for M&A in 2016?
What companies are still out on the prowl for M&A deals?
What companies constitute the most likely targets?
$437bn worth of deals has been completed in 2015 for pharmaceutical and biotechnology companies.
Biggest deal: Pfizer’s $160bn deal for Allergan will becomes the biggest deal in the industry’s history
Biggest spenders: Companies in Datamonitor Healthcare’s PharmaVitae portfolio were involved in $385bn worth of deals
Portfolio transformation: Companies continue to explore asset stripping
Targeted deal-making: Companies continue to gain a larger foothold in therapeutic areas of strength
Tax-inversions: Tax-inversions have spilt over in 2015
2016 Outlook: Pipeline-centric acquisitions will continue to bolster companies that have remained largely passive
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.